微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2011, Vol. 3 ›› Issue (3): 210-213.doi: 10.3969/j.issn.1674-5671.2011.03.08

• 临床研究 • 上一篇    下一篇

弥漫大B细胞淋巴瘤患者血浆MGMT基因甲基化与化疗疗效关系

康马飞, 骆梅青, 刘瑛, 廖漓漓, 陈莹   

  • 出版日期:2011-09-25 发布日期:2011-10-17
  • 基金资助:

    广西卫生厅科研基金资助课题（Z 2008271）

Relationship between methylation of MGMT gene in plasma of patients with diffuse large B-cell lymphoma and efficacy of chemotherapy

KANG Ma-Fei, LUO Mei-Qing, LIU Ying, LIAO Li-Li, CHEN Ying   

  • Online:2011-09-25 Published:2011-10-17

PDF (PC)

420

赞

被引次数

8

摘要： 目的 检测弥漫大B细胞淋巴瘤（DLBCL）患者外周血血浆中O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase，MGMT)基因的甲基化状态，探讨MGMT基因甲基化与含烷化剂方案治疗DLBCL疗效的关系。方法 利用巢式甲基化特异性聚合酶链反应法检测CHOP方案治疗前后DLBCL患者外周血血浆MGMT基因的甲基化状态。结果 30例DLBCL患者血浆MGMT基因甲基化率为63.3%（19/30），血浆MGMT基因甲基化者化疗有效率为100.0%（19/19），非甲基化者化疗有效率为72.7%（8/11），两组化疗有效率差异有统计学意义（P=0.041）。血浆MGMT基因甲基化者化疗后耐药发生率为10.5%（2/19），非甲基化者耐药发生率为54.5%（6/11），两组化疗耐药率差异有统计学意义（P=0.028）。结论 外周血血浆中MGMT基因甲基化可能是预示DLBCL使用含烷化剂方案化疗疗效和耐药的指标。

关键词: 淋巴瘤, 弥漫大B细胞淋巴瘤,  , MGMT基因, DNA甲基化, 化学疗法

Abstract: Objective To detect the methylation of gene O6-methylguanine DNA methyltransferase (MGMT) in peripheral plasma of patients with diffuse large B-cell lymphoma (DLBCL)，and to evaluate the relationship between methylation of MGMT and efficacy of chemotherapy on DLBCL.Methods  Before and after chemotherapy，nestedmethylation specific PCR (nMSP) was performed for detecting methylation of MGMT in plasma from DLBCL patients who were treated with CHOP.Result Methylation of MGMT was found in 63.3% (19/30) of patients with DLBCL.The response rates were 100% (19/19) in patients with methylation of MGMT and 72.7% (8/11) in patients with non-methylation of MGMT，and the difference between two groups was statistically significant (P=0.041).The ratios of resistance to chemotherapy were 10.5% (2/19) in patients with methylation of MGMT and 54.5% (6/11) in patients with non-methylation of MGMT，and the difference between two groups was statistically significant (P=0.028).Conclusion Methylation of MGMT in peripheral plasma of DLBCL patients might be a biomarker of response or resistant to chemotherapy with alkylating agents based regimens.

Key words: Lymphoma, Diffuse large B-cell lymphoma (DLBCL), MGMT gene, DNA methylation, Chemotherapy